A Missing Hallmark of Cancer: Dysregulation of Differentiation

TL;DR

This paper argues that dysregulated differentiation should be recognized as a universal hallmark of cancer due to its mechanistic distinctiveness and clinical relevance, including prognosis and therapy targeting.

Contribution

It establishes dysregulated differentiation as a new, distinct hallmark of cancer with significant clinical utility, expanding the framework of cancer characterization.

Findings

Dysregulated differentiation is present in nearly all cancers.

It is mechanistically distinct from growth inhibition.

It has clinical utility in prognosis and therapy.

Abstract

Cancer cells possess a nearly universal set of characteristics termed the hallmarks of cancer, including replicative immortality and resisting cell death. Dysregulated differentiation is present in virtually all cancers yet has not yet been described as a cancer hallmark. Like other hallmarks, dysregulated differentiation involves a breakdown of the cellular cooperation that typically makes multicellularity possible - in this case disrupting the division of labor among the cells of a body. At the time that the original hallmarks of cancer were described, it was not known that dysregulated differentiation was mechanistically distinct from growth inhibition, but now that this is known, it is a further reason to consider dysregulated differentiation a hallmark of cancer. Dysregulated differentiation also has clinical utility, as it forms the basis of pathological grading, predicts clinical outcomes, and is a viable target for therapies aimed at inducing differentiation. Here we argue that hallmarks of cancer should be near universal, mechanistically distinct, and have clinical utility for prognosis and/or therapy. Dysregulated differentiation meets all of these criteria.